Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

• Main Authors: Chng, W-J, Goldschmidt, H, Dimopoulos, MA, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Feng, S, Aggarwal, S, Hajek, R
• Other Authors: DEAN'S OFFICE (MEDICINE)
• Format: Article
• Language: English
• Published: NATURE PUBLISHING GROUP 2022
• Subjects: Science & Technology; Life Sciences & Biomedicine; Oncology; Hematology; LOW-DOSE DEXAMETHASONE; STEM-CELL TRANSPLANTATION; PLUS DEXAMETHASONE; INTERGROUPE FRANCOPHONE; DELETION 17P; LENALIDOMIDE; THERAPY; ABNORMALITIES; POMALIDOMIDE; THALIDOMIDE
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/229014
• Institution: National University of Singapore

10.1038/leu.2016.390